PUBLIC COMPANY
save$BLTEBELITE BIO, INC
$BLTE154.19+7.68%San Diego, CA, USupdated 9d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
- phase3A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
- phase3Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
🐶 Hiring Signal
News
- City banks nearly $100M for next-gen RNAi drugsCo-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.biopharma_dive · 5mo ago
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that